v2.4.0.6

Collaboration Arrangements (Details) (USD $) | 12 Months Ended |  | 1 Months Ended | 12 Months Ended |  | 1 Months Ended | 12 Months Ended |  | 12 Months Ended | 1 Months Ended |  | 12 Months Ended |  |  | 12 Months Ended |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2011 GSK | Dec. 31, 2010 GSK | Dec. 31, 2009 GSK | Dec. 31, 2011 Astellas | Nov. 30, 2011 Class A common stock GSK | Aug. 31, 2011 Class A common stock GSK | Jul. 31, 2011 Class A common stock GSK | May 31, 2011 Class A common stock GSK | Feb. 28, 2011 Class A common stock GSK | Dec. 31, 2011 Common Stock | Dec. 31, 2010 Common Stock | Dec. 31, 2002 Long-acting beta agonist (LABA) collaboration Preferred stock Series E Glaxo Group Limited, an affiliate of GSK | Dec. 31, 2011 Long-acting beta agonist (LABA) collaboration LAMA/LABA Maximum | Dec. 31, 2011 Long-acting beta agonist (LABA) collaboration LABA/RELOVAIR collaboration Y product | Dec. 31, 2010 Long-acting beta agonist (LABA) collaboration LABA/RELOVAIR collaboration | Dec. 31, 2009 Long-acting beta agonist (LABA) collaboration LABA/RELOVAIR collaboration | Dec. 31, 2011 Strategic alliance with GSK | Oct. 31, 2004 Strategic alliance with GSK Class A common stock GlaxoSmithKline LLC, an affiliate of GSK | May 31, 2004 Strategic alliance with GSK Class A common stock GlaxoSmithKline LLC, an affiliate of GSK | Nov. 30, 2010 Strategic alliance with GSK Common Stock Glaxo Group Limited, an affiliate of GSK | Dec. 31, 2009 Strategic alliance with GSK LAMA | Dec. 31, 2011 Strategic alliance with GSK LAMA | Dec. 31, 2011 Strategic alliance with GSK MABA product | Dec. 31, 2010 Strategic alliance with GSK MABA | Dec. 31, 2009 Strategic alliance with GSK MABA | Aug. 31, 2011 Strategic alliance with GSK MABA containing '081 | Dec. 31, 2011 Strategic alliance with GSK MABA containing '081 | Dec. 31, 2011 Strategic alliance with GSK MABA containing '081 - single agent | Dec. 31, 2011 Strategic alliance with GSK MABA containing '081 - single agent Maximum | Dec. 31, 2011 Strategic alliance with GSK MABA containing '081 - single agent Minimum | Dec. 31, 2011 Strategic alliance with GSK MABA containing '081 - combination product | Dec. 31, 2011 Strategic alliance with GSK MABA containing additional MABA product | Oct. 31, 2011 Strategic alliance with GSK MABA containing additional MABA | Dec. 31, 2011 Strategic alliance with GSK MABA containing additional MABA Maximum | Dec. 31, 2011 Strategic alliance with GSK MABA containing additional MABA - single agent | Dec. 31, 2011 Strategic alliance with GSK MABA containing additional MABA - single agent Maximum | Dec. 31, 2011 Strategic alliance with GSK MABA containing additional MABA - single agent Minimum | Dec. 31, 2011 Strategic alliance with GSK MABA containing additional MABA - combination product | Dec. 31, 2011 Strategic alliance with GSK Non-license specific | Dec. 31, 2010 Strategic alliance with GSK Non-license specific | Dec. 31, 2009 Strategic alliance with GSK Non-license specific | Dec. 31, 2011 License, Development and Commercialization Agreement With Astellas | Dec. 31, 2011 License, Development and Commercialization Agreement With Astellas VIBATIV | Dec. 31, 2010 License, Development and Commercialization Agreement With Astellas VIBATIV | Dec. 31, 2009 License, Development and Commercialization Agreement With Astellas VIBATIV | Jan. 06, 2012 License, Development and Commercialization Agreement With Astellas VIBATIV Y | Dec. 31, 2011 License, Development and Commercialization Agreement With Astellas VIBATIV Astellas | Dec. 31, 2010 License, Development and Commercialization Agreement With Astellas VIBATIV Astellas
Information related to collaboration arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum obligation for milestone payments to GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 220,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of combination products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
If global regulatory authorities accept the applications for RELOVAIR, which the Company anticipates will be filed by GSK beginning in mid-2012, a portion of these potential milestone payments could be payable to GSK within the next two years. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate for first level of annual global net sales (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% | 10.00% |  |  |  |  |  | 15.00% | 10.00% |  |  |  |  |  |  |  |  |  |  |
Royalty rate for combination products as a percentage of the rate applied to single products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 70.00% |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |
Royalty rate for sales above first level of annual global net sales (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.50% |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties payable to Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% | 2.00% |  |  |  |  |
Annual global sales level used to determine royalty rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,500,000,000 |  |  |  |  |  |  | 3,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of products which Company is obligated to use diligent efforts to discover after license of a program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of combination products to be developed and commercialized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential upfront license and milestone payments that Company could receive |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential upfront license and milestone payments that Company could receive in respect of combination medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 129,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity's common stock information |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock Shares Purchased |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,625,000 |  |  |  |  |  |  | 433,757 | 6,387,096 | 5,750,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate Amounts |  | 93,478,000 |  |  |  |  |  |  |  |  |  |  |  | 86,000 |  |  |  |  |  |  | 6,900,000 | 108,900,000 | 129,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase price of shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 40,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock for cash in private placement to a related party (in shares) |  |  |  |  |  |  |  | 58,411 | 102,466 |  | 261,299 | 152,278 | 574,000 | 5,750,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock for cash in private placement to a related party | 13,618,000 | 129,190,000 |  |  |  |  |  | 1,298,000 | 2,020,000 |  | 6,689,000 | 3,609,000 | 5,000 | 58,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares of Class A common stock converted into common stock |  |  |  |  |  |  |  |  |  | 9,401,499 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares of Class A stock convertible into one share of common stock |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares of common stock into which one share of Class A stock can be converted |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
GSK Upfront License Fees, Milestone Payments and Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront License Fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  | 41,000,000 |  |  |  |  | 5,000,000 | 6,000,000 |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |
Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  | 69,000,000 |  |  |  |  | 3,000,000 | 16,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000 |  |  | 110,000,000 |  |  |  |  | 8,000,000 | 22,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of royalty payment (in years) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 |  |
License, Development and Commercialization Agreement with Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license, milestone and other fees received |  |  |  |  |  |  | 191,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenue recognized under the collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization of deferred revenue |  |  |  | 9,658,000 | 9,826,000 | 15,073,000 |  |  |  |  |  |  |  |  |  |  | 4,718,000 | 5,081,000 | 5,081,000 |  |  |  |  | 4,240,000 |  | 3,082,000 | 2,007,000 | 3,014,000 |  |  |  |  |  |  | 936,000 |  |  |  |  |  |  | 1,858,000 | 2,738,000 | 2,738,000 |  |  |  |  |  |  |
Amortization of deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,975,000 | 12,975,000 | 11,338,000 |  |  |
Royalties from net sales of VIBATIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,422,000 | 1,123,000 | 766,000 |  |  |
Proceeds from VIBATIV delivered to Astellas | 24,512,000 | 24,223,000 | 24,374,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,171,000 | 2,058,000 |  |  | 1,171,000 | 2,058,000
Cost of VIBATIV delivered to Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (1,177,000) | (938,000) | (1,629,000) |  |  |
Cost of unrealizable VIBATIV inventory |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (537,000) | (821,000) | (1,175,000) |  |  |
Total net revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 14,854,000 | $ 14,397,000 | $ 9,300,000 |  |  |

X
- Definition Represents the annual royalties to be received by the entity from the other party in a collaborative arrangement, as a percentage of net sales. + References No definition available. + Details
Name: | thrx_AnnualRoyaltiesPercentageOfNetSales
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of shares of Class A stock in the conversion ratio for conversion of Class A into common stock. + References No definition available. + Details
Name: | thrx_ClassAToCommonConversionRatioClassA
Namespace Prefix: | thrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of shares of common stock in the conversion ratio for conversion of Class A into common stock. + References No definition available. + Details
Name: | thrx_ClassAToCommonConversionRatioCommon
Namespace Prefix: | thrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of structurally different product candidates which the entity is obligated to use diligent efforts to discover at its own cost after the collaborator licenses a program. + References No definition available. + Details
Name: | thrx_CollaborationArrangementObligationToDiscoverStructurallyDifferentProductsAfterLicense
Namespace Prefix: | thrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the revenue recognized from all sources, including amortization of deferred revenue, royalties from product sales, and revenue from product sales less the costs of delivered product and other charges directly related to the product. + References No definition available. + Details
Name: | thrx_CollaborationArrangementRevenueNet
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the rate of royalty payable to the counterparty pursuant to terms of termination agreement of a collaboration agreement. + References No definition available. + Details
Name: | thrx_CollaborativeAgreementTerminationRateOfRoyaltyPayable
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period for which of royalty is payable to the counterparty pursuant to terms of termination agreement of a collaboration agreement. + References No definition available. + Details
Name: | thrx_CollaborativeAgreementTerminationRoyaltyPayableTerm
Namespace Prefix: | thrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | thrx_CollaborativeArrangementAbstract
Namespace Prefix: | thrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period within which a portion of the potential milestone payments could be payable. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementBeginningOfMilestonePaymentsPeriod
Namespace Prefix: | thrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum obligation for milestone payments under a collaborative arrangement, if both a single-agent and a combination product or two different combination products are launched under the collaborative arrangement in multiple regions of the world. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementMaximumObligationForMilestonePayments
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of milestone payments receivable as of the balance sheet date. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementMilestonePaymentsReceivable
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the cumulative amount of milestone payments received under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementMilestonePaymentsReceived
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of combination products which are agreed to be developed and commercialized under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementNumberOfCombinationProductsToBeDevelopedAndCommercialized
Namespace Prefix: | thrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of combination products which may be launched under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementNumberOfCombinationProductsToBeLaunched
Namespace Prefix: | thrx_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents potential future revenue from upfront and milestone payments under a collaborative arrangement for programs with single-agent medicines. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementPotentialFutureRevenueFromUpfrontAndMilestonePaymentsCombinationAgentMedicines
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents potential future revenue from upfront and milestone payments under a collaborative arrangement for programs with single-agent medicines. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementPotentialFutureRevenueFromUpfrontAndMilestonePaymentsSingleAgentMedicines
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | thrx_CollaborativeArrangementRevenueAbstract
Namespace Prefix: | thrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate for combination products as a percentage of the rate applicable for single products under a collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementRoyaltyRateCombinationProductsAsPercentageOfSingleProducts
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix: | thrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the cumulative amount of upfront fees received under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementUpfrontFeesReceived
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the cash inflow during the period from receipt of milestone payments specified in a collaborative arrangement. + References No definition available. + Details
Name: | thrx_ProceedsFromCollaborativeArrangmentMilestonePayment
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares issued during the period as a result of private placement to a related party. + References No definition available. + Details
Name: | thrx_StockIssuedDuringPeriodSharesPrivatePlacementToRelatedParty
Namespace Prefix: | thrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the value of shares issued during the period related to a collaboration arrangement. + References No definition available. + Details
Name: | thrx_StockIssuedDuringPeriodValueNewIssuesCollaborationArrangement
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value stock issued during the period as a result of private placement to a related party, net of issuance cost. + References No definition available. + Details
Name: | thrx_StockIssuedDuringPeriodValuePrivatePlacementToRelatedParty
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the cumulative amount of total upfront fees and milestone payments received under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_UpfrontAndMilestonePaymentsReceived
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the cumulative amount of upfront, milestone and other payments received under the collaborative arrangement. + References No definition available. + Details
Name: | thrx_UpfrontMilestoneAndOtherFeesReceived
Namespace Prefix: | thrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 32 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 + Details
Name: | us-gaap_ConversionOfStockSharesConverted1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total costs related to goods produced and sold during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Article 5 -Section 03 -Paragraph 2 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 + Details
Name: | us-gaap_CostOfGoodsSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4542-108314 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 4 -Section 7 -Paragraph 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 86 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. + Details
Name: | us-gaap_InventoryWriteDown
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Article 5 -Section 03 -Paragraph 1 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 + Details
Name: | us-gaap_OtherSalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A -Subsection 1 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 + Details
Name: | us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RevenueRecognitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Article 5 -Section 03 -Paragraph 1 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration